Viewing Study NCT02753595

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:39 PM
Ignite Modification Date: 2026-02-06 @ 1:51 PM
Study NCT ID: NCT02753595
Status: TERMINATED
Last Update Posted: 2020-07-13
First Post: 2016-04-26
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)
Sponsor: Eisai Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PEGylated Recombinant Human Hyaluronidase View
None Eribulin Mesylate View
None E7389 View
None PEGPH20 View
None Human Epidermal Growth Factor Receptor 2-Negative View
None High-Hyaluronan View